01.19.18
Ivan Møller has been appointed to a new position as senior vice president, Technical Development & Operations, Zealand Pharma. Mr. Møller joins Zealand as a new member of the management team, effective March 1, 2018.
Mr. Møller has extensive experience having held numerous senior management positions in the international pharmaceutical industry, including roles at Novartis in both generics and pharmaceutical manufacturing, as well as strategy, quality assurance, contract manufacturing and supply chain leadership in Germany, the U.S. and Switzerland. Prior to Novartis, he was project leader at The Boston Consulting Group in New York, where he led client engagements in the pharmaceutical R&D and manufacturing areas.
Britt Meelby Jensen, president and chief executive officer at Zealand, said, "I am pleased to welcome Ivan Møller to Zealand to lead Technical Development & Operations. He has a strong track record as well as extensive U.S. and European experience. For our business, it is a new and important role, created as a natural consequence of our growing late stage pipeline and our ambition to bring our own medicines to market within specialty diseases. I am convinced that Ivan is well suited to lead this important area, contributing to the success of Zealand."
Mr. Møller has extensive experience having held numerous senior management positions in the international pharmaceutical industry, including roles at Novartis in both generics and pharmaceutical manufacturing, as well as strategy, quality assurance, contract manufacturing and supply chain leadership in Germany, the U.S. and Switzerland. Prior to Novartis, he was project leader at The Boston Consulting Group in New York, where he led client engagements in the pharmaceutical R&D and manufacturing areas.
Britt Meelby Jensen, president and chief executive officer at Zealand, said, "I am pleased to welcome Ivan Møller to Zealand to lead Technical Development & Operations. He has a strong track record as well as extensive U.S. and European experience. For our business, it is a new and important role, created as a natural consequence of our growing late stage pipeline and our ambition to bring our own medicines to market within specialty diseases. I am convinced that Ivan is well suited to lead this important area, contributing to the success of Zealand."